PET radiopharmaceuticals such as Glu-NH-CO-NH-Lys-(Ahx)-[68Ga]-HBED (68Ga-PSMA-11) use this ligand binding for the purpose of prostate cancer imaging, particularly in patients with biochemical recurrence (3). Here, FOLH1 is linked to prostate carcinoma.